# New clinical data, new deck — and an FDA meeting on July 1 | Sen-Jam Pharmaceutical

- Canonical URL: https://wefunder.com/feed/336355
- Entity ID: wefunder:feed_item:336355
- Published at: 2026-06-13 17:58:12 UTC
- Updated at: 2026-06-18 02:15:32 UTC

## Author
Jim Iversen

## Subject
Sen-Jam Pharmaceutical

## Content
Dear Wefunder Investors & Community,Three quick updates from Sen-Jam:1. Clinical results — video link. Two trials converged on one patented biomarker signature (NLR) — our proof that this is a platform, not a single drug.2. New investor deck — link. The clearest picture yet of our biology-of-resilience platform.3. FDA End-of-Phase 2 meeting — July 1, 2026. A major catalyst for SJP-001, which is now Phase 3 ready.Sen-Jam’s Reg D bridge round is now open at a $150M valuation. Proceeds will advance SJP-001 toward Phase 3 and position the company for its fall financing, which is anchored by TASK Clinical’s commitment to invest $5M at a $300M valuation.Investors can visit the campaign page to review the opportunity and participate or add to their position.→ Visit the campaign: https://wefunder.com/senjam→ Schedule a call with me: calendly.com/jiversenNew website coming and Atlas update coming next week.Be well, safe, and inspired,Jim